


International Parkinson and
Movement Disorder Society
Asian & Oceanian Section

6th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress

April 12-14, 2019 • Hangzhou



Program-At-A-Glance



Dear Colleagues,

The International Parkinson and Movement Disorder Society (MDS) and the MDS Asian and Oceanic Section (MDS-AOS) warmly invite you to attend 6th Asian and Oceanic Parkinson's Disease and Movement Disorders Congress (AOPMC), April 12-14, 2019 in Hangzhou.

The AOPMC occurs every two years as a forum to further develop the field of Movement Disorders in the region. Please join us to facilitate communication between clinicians and researchers in the region, disseminate updated knowledge about movement disorders, improve quality of life and independence of movement disorders patients and caregivers, promote research and facilitate research collaborations in movement disorders and expose clinicians, researchers and healthcare professionals in the region to movement disorders initiatives.

We look forward to welcoming you to Hangzhou in April 2019.



Baorong Zhang
Chair, 6th AOPMC Scientific Program
Committee
and
Chair, 6th AOPMC Local Organizing
Committee



Beomseok Jeon
Chair, 6th AOPMC Oversight Committee
and
Chair, MDS-AOS, 2017-2019



AOPMC Schedule-At-A-Glance

	Friday, April 12	Saturday, April 13	Sunday, April 14
8:00		Plenary Session 8:00-9:30	MDS-AOS Lectureship Awards 8:00-9:30
8:30			
9:00		Tea/Coffee Break 9:30-10:00	Tea/Coffee Break 9:30-10:00
9:30		Plenary Session 10:00-11:30	Plenary Session 10:00-11:30
10:00			
10:30		Poster Session/Late-Breaking Poster Session/Guided Poster Tours 11:30-12:30	Poster Session/ Guided Poster Tours 11:30-12:30
11:00			
11:30		Break 12:30-13:00	Break 12:30-13:00
12:00	Sponsored Lunch Symposium 12:00-13:00		
12:30		Sponsored Lunch Symposium 13:00-14:00	Sponsored Lunch Symposium 13:00-14:00
13:00	Break 13:00-13:15		
13:30	Corporate Symposium 13:15-14:15	Break 14:00-14:30	Break 14:00-14:30
14:00	Break 14:15-14:30		
14:30	Corporate Symposium 14:30 - 15:30	Parallel Sessions 14:30-16:00	Parallel Sessions 14:30-16:00
15:00	Tea/Coffee Break 15:30-16:00		
15:30		Tea/Coffee Break 16:00-16:30	Break 16:00-16:30
16:00	Corporate Symposium 16:00-17:00		
16:30		Parallel Sessions 16:30-18:00	Parallel Sessions 16:30-18:00
17:00	Break 17:00-17:15		
17:30	Corporate Symposium 17:15-18:15	Break 18:00-18:30	
18:00	Break 18:15-18:30		
18:30	Welcome Ceremony 18:30-19:30	Video Tournament 18:30-20:30	
19:00	Opening Reception 19:30-20:00		
19:30			
20:00			



Saturday, April 13, 2019

2101 Plenary Session

Specific Movement Disorders in the Asian-Oceanian Region: Historical and Recent Developments

8:00 - 9:30

Chairs: Haibo Chen, *Beijing*
Beomseok Jeon, *Seoul*

8:00 X-linked Dystonia Parkinsonism: A
Filipino Disease, A Global Effort
Roland Dominic Jamora, *Manila*

8:30 Amyotrophic Lateral Sclerosis/
Parkinsonism Dementia Complex
in the Kii Peninsula
Yasumasa Kokubo, *Tsu City*

9:00 Paroxysmal Dyskinesia and
Genetics with Focus on PRRT2
Zhi-Ying Wu, *Hangzhou*

At the conclusion of this session, participants should be better able to:

1. Recognize the new developments in the diagnosis and management of X-linked dystonia parkinsonism
2. Recognize the recent developments in the field of ALS/PDC in the Kii Peninsula
3. Discuss the development in the genetics of paroxysmal dyskinesias with special focus on PRRT2

2102 Plenary Session

Genotype-Phenotype Correlation in Ataxia: An Asian Perspective

10:00 - 11:30

Chairs: Chon-Haw Tsai, *Taichung*
Hirohisa Watanabe, *Nagoya*

10:00 The Pathogenesis of Hereditary
Ataxia and the Treatment
Strategy
Kinya Ishikawa, *Tokyo*

10:30 Genotype-Phenotype Correlation
in Ataxia
Han-Joon Kim, *Seoul*

11:00 Treatable Ataxia, Not-to-Miss
Yih-Ru Wu, *Taipei*

At the conclusion of this session, participants should be better able to:

1. Explain the pathogenesis of hereditary ataxia and how to treat
2. Describe the genotype-phenotype correlation
3. Identify the treatable ataxia

2203 Parallel Session

Preclinical and Prodromal Parkinson's Disease: Past, Present and Future

14:30 - 16:00

Chairs: Louis Tan, *Singapore*

14:30 Pathophysiology of Parkinson's
Disease
Carolyn Sue, *Sydney*

15:00 Clinical Biomarkers of Parkinson's
Disease
TBA

15:30 Is Diagnosis of Prodromal
Parkinson's Disease Feasible?
Anthony Lang, *Toronto*

At the conclusion of this session, participants should be better able to:

1. Describe the recent progress in the understanding of pathogenesis of Parkinson's disease
2. Discuss the range of clinical markers and their application in identifying Parkinson's disease including prodromal stage
3. Integrate our understanding of the progression of Parkinson's disease from the prodromal stage

2204 Parallel Session

Unfamiliar Symptoms in Familiar Movement Disorders

14:30 - 16:00

Chairs: Shengdi Chen, *Shanghai*
Pramod Pal, *Bengaluru*

14:30 Under-Recognized Motor
and Non-Motor Symptoms in
Parkinson's Disease and Parkinson
Plus Syndrome
TBA

15:00 Extra-Cerebellar Signs and
Symptoms in Spinocerebellar
Ataxias
Jin Whan Cho, *Seoul*

15:30 Atypical Presentation of Genetic
Dystonia
Victor Fung, *Sydney*

At the conclusion of this session, participants should be better able to:

1. Identify the under-recognized motor and non-motor symptoms in Parkinson's disease and Parkinson plus syndrome
2. Describe extra-cerebellar signs and symptoms in spinocerebellar ataxias
3. Describe atypical presentation of well-known genetic dystonia

2205 Parallel Session

Focusing on New Targets for Therapy in Movement Disorders

14:30 - 16:00

Chairs: Simon Lewis, *Sydney*

14:30 The New Frontier – Disease
Modification for Parkinson's
Disease
Nobutaka Hattori, *Tokyo*

15:00 Advances in the Understanding
and Treatment of
Channelopathies
Chon-Haw Tsai, *Taichung*

15:30 New Horizons for Botulinum
Injections in Movement Disorders
Raymond Rosales, *Quezon City*

At the conclusion of this session, participants should be better able to:

1. Describe the landscape of disease modifying therapies in Parkinson's disease
2. Summarize the pathomechanism and emerging treatment of channelopathies
3. Discuss the expanding role of botulinum toxin injection for the treatment of movement disorders

2306 Parallel Session

Hot Topics in Parkinson's Disease Non-Motor Symptoms

16:30 - 18:00

Chairs: Chunfeng Liu, *Suzhou*

16:30 Treatment of Sleep Disorders in
Parkinson's Disease
Jawad Bajwa, *Riyadh*

17:00 Neuropsychiatric Symptoms in
Parkinson's Disease
Jee-Young Lee, *Seoul*

17:30 Bladder and Sexual Dysfunction
in Parkinson's Disease
Priya Jagota, *Bangkok*

At the conclusion of this session, participants should be better able to:

1. Discuss the presentation and management of sleep disorders in Parkinson's disease
2. Discuss the presentation and management of neuropsychiatric symptoms in Parkinson's disease
3. Discuss the pathophysiology and management of bladder and sexual dysfunction in Parkinson's disease

Saturday, April 13, 2019

2307 Parallel Session

Nondopaminergic System in Parkinson's Disease 16:30 - 18:00

- Chairs: Oscar Gershanik, *Buenos Aires*
 Baorong Zhang, *Hangzhou*
- 16:30 Norepinephrine and Parkinson's Disease
 Eng-King Tan, *Singapore*
- 17:00 Serotonin and Parkinson's Disease
 TBA
- 17:30 Acetylcholine and Parkinson's Disease
 Chin-Hsien Lin, *Taipei*

At the conclusion of this session, participants should be better able to:

1. Understand the neuroanatomy and physiology of norepinephrine and clinical implication in Parkinson's disease
2. Understand the neuroanatomy and physiology of serotonin and clinical implication in Parkinson's disease
3. Understand the neuroanatomy and physiology of acetylcholine system and clinical implication in Parkinson's disease

2308 Parallel Session

Chorea in Clinical Practice 16:30 - 18:00

- Chairs: Huifang Shang, *ChengDu*
 Thomas Kimber, *Adelaide*
- 16:30 Update on Genetics and Molecular Imaging in Huntington's Disease
 Thomas Kimber, *Adelaide*
- 17:00 The Most Frequent Forms of Genetic and Acquired Chorea in Clinical Practice
 Mohit Bhatt, *Santa Cruz West*
- 17:30 New Treatment Strategies in Huntington's Disease and Other Chorea
 Hitoshi Okazawa, *Tokyo*

At the conclusion of this session, participants should be better able to:

1. Recognize recent developments in genetics of Huntington's disease and identify a comprehensive view of molecular imaging biomarkers to study Huntington's disease
2. Recognize the phenomenology of Huntington's disease and other disorders (Huntington's disease-like syndromes) in which chorea is the main clinical feature
3. Define the latest pharmaceutical and surgical treatment in Huntington's disease and other chorea

Video Tournament

18:30 - 20:30

This interactive tournament will challenge participants to improve diagnostic skills with unique and interesting cases.

- Hosts: Victor Fung, *Sydney*
 Anthony Lang, *Toronto*

Sunday, April 14, 2019

3101 Plenary Session

MDS-AOS Lectureship Awards 8:00 - 9:30

- 8:00 Philip Thompson Lecture
 Shengdi Chen, *Shanghai*
- 8:30 Yoshikuni Mizuno Lecture
 Ruey-Meei Wu, *Taipei*

At the conclusion of this session, participants should be better able to:

1. Describe the pharmacological and surgical therapeutic options for Parkinson's disease from an evidence-based perspective
2. Discuss physical exercise, speech therapy, occupational therapy and other non-pharmacological management strategies for Parkinson's disease
3. Identify the principles of a palliative care approach to managing Parkinson's disease and related conditions

At the conclusion of this session, participants should be better able to:

1. Review aspects of gastrointestinal dysfunction in Parkinson's disease
2. Discuss the role of gastrointestinal infections and microbiome in Parkinson's disease
3. Review causes of weight loss and management strategies in Parkinson's disease

3102 Plenary Session

Comprehensive Management of Parkinson's Disease 10:00 - 11:30

- Chairs: Günther Deuschl, *Kiel*
- 10:00 Evidence-Based Management of Parkinson's Disease
 Shen-Yang Lim, *Petaling Jaya*
- 10:30 Management of Parkinson's Disease: A Non-Pharmacological Perspective
 Louis Tan, *Singapore*
- 11:00 Palliative Care for Parkinsonian Disorders: Why and How?
 Vinay Goyal, *New Delhi*

3203 Parallel Session

Gastrointestinal Dysfunction, Weight Loss and Nutritional Aspects in Parkinson's Disease 14:30 - 16:00

- Chairs: Yun Kim, *Seoul*
 Lijuan Wang, *Guangzhou*
- 14:30 Gastrointestinal Dysfunction in Parkinson's Disease
 Ai Huey Tan, *Kuala Lumpur*
- 15:00 Gastrointestinal Infections and Microbiome in Parkinson's Disease
 Qin Xiao, *Shanghai*
- 15:30 Weight Loss and Nutrition in Parkinson's Disease, and Management Strategies
 Yasuyuki Okuma, *Izunokuni*

3204 Parallel Session

Clinical Diagnostic Pointers in Making a Diagnosis of a Movement Disorder Condition 14:30 - 16:00

- Chairs: Shen-Yang Lim, *Petaling Jaya*
- 14:30 Differential Diagnosis of Parkinsonian Disorders
 Baorong Zhang, *Hangzhou*
- 15:00 Phenomenology of Hyperkinetic Movement Disorders
 Thien Thien Lim, *Tanjung Bunga*
- 15:30 Diagnosis of Functional Movement Disorders
 Oscar Gershanik, *Buenos Aires*

At the conclusion of this session, participants should be better able to:

1. Explain features that distinguish the different parkinsonian syndromes
2. Categorize hyperkinesia and list appropriate differential diagnoses
3. Recognize characteristics of functional movement disorders



Sunday, April 14, 2019

3205 Parallel Session

STN-DBS for Parkinson's Disease at an Earlier Stage 14:30 - 16:00

Chairs: Vincent Mok, *Hong Kong*
Chon-Haw Tsai, *Taichung*

14:30 Knowledge, Attitude and Myths of DBS in Patients with Parkinson's Disease and Their Caregivers
Pramod Pal, *Bengaluru*

15:00 Non-Motor Issues in DBS: Neuropsychiatric Effects and Long Term Outcome
Young Eun Kim, *Sungnam*

15:30 How Early STIM Study Changes Selection Criteria
Günther Deuschl, *Kiel*

At the conclusion of this session, participants should be better able to:

1. Discuss the patient perspective of neuromodulation
2. Describe the neuropsychiatric effects and long term outcome of neuromodulation
3. Discuss the recent data on early STIM study and how it may change patient selection

3306 Parallel Session

Defrosting Parkinson's Disease: Understanding and Managing Freezing of Gait and Falls 16:30 - 18:00

Chairs: Weidong Le, *Dalian*
Yasuyuki Okuma, *Izunokuni*

16:30 The Clinical Manifestations and Impacts of Gait Disturbance, Freezing and Falls in Parkinson's Disease
Sue Lord, *Auckland*

17:00 Unlocking the Phenomenology of Freezing with Novel Investigative Techniques
Mac Shine, *North Ryde*

17:30 Treating Freezing and Falls - Strategies Old and New
TBA

At the conclusion of this session, participants should be better able to:

1. Recall the clinical associations of freezing of gait and falls in Parkinson's disease
2. Appreciate the pathophysiology underlying gait disorder in Parkinson's disease
3. Summarize the current strategies to reduce freezing and falls in Parkinson's disease

3307 Parallel Session

Movement Disorders in Vascular Diseases and Hydrocephalus 16:30 - 18:00

Chairs: Asha Kishore, *Trivandrum*
Qing Wang, *Guangzhou*

16:30 Stroke Induced Movement Disorders – Spectrum and Management
Arlene Ng, *Quezon City*

17:00 Small Vessel Disease and Parkinsonism – Evolving Concepts
Hirohisa Watanabe, *Nagoya*

17:30 Hydrocephalus and Parkinsonism – Manifestation and Management
Rupam Borgohain, *Hyderabad*

At the conclusion of this session, participants should be better able to:

1. Discuss the spectrum and management of stroke induced movement disorders and strategic lesion locations
2. Discuss the evolving pathogenetic concepts and clinical application of small vessel disease and parkinsonism
3. Identify the optimal balance between medical and surgical management and the clinical complexity of Hydrocephalus and Parkinsonism

3308 Parallel Session

Biomarkers for Parkinson's Disease 16:30 - 18:00

Chairs: Nobutaka Hattori, *Tokyo*
Ruey-Meei Wu, *Taipei*

16:30 New Biomarkers for Parkinson's Disease
Shinji Saiki, *Tokyo*

17:00 Neuroimaging Biomarkers for Parkinson's Disease
Jong-Min Kim, *Seongnam*

17:30 Clinical Biomarkers for Parkinson's Disease
Roongroj Bhidayasiri, *Bangkok*

At the conclusion of this session, participants should be better able to:

1. Discuss metabolome as a biomarker
2. Discuss neuroimaging as a clinical marker
3. Identify the clinical signs as a phenotypic biomarker

For more information
or to register, visit
www.aopmc.org